Proton range uncertainty caused by synthetic computed tomography generated with deep learning from pelvic magnetic resonance imaging.

BACKGROUND

In proton therapy, it is disputed whether synthetic computed tomography (sCT), derived from magnetic resonance imaging (MRI), permits accurate dose calculations. On the one hand, an MRI-only workflow could eliminate errors caused by, e.g., MRI-CT registration. On the other hand, the extra error would be induced due to an sCT generation model. This work investigated the systematic and random model error induced by sCT generation of a widely discussed deep learning model, pix2pix.

MATERIAL AND METHODS

An open-source image dataset of 19 patients with cancer in the pelvis was employed and split into 10, 5, and 4 for training, testing, and validation of the model, respectively. Proton pencil beams (200 MeV) were simulated on the real CT and generated sCT using the tool for particle simulation (TOPAS). Monte Carlo (MC) dropout was used for error estimation (50 random sCT samples). Systematic and random model errors were investigated for sCT generation and dose calculation on sCT.

RESULTS

For sCT generation, random model error near the edge of the body (∼200 HU) was higher than that within the body (∼100 HU near the bone edge and <10 HU in soft tissue). The mean absolute error (MAE) was 49 ± 5, 191 ± 23, and 503 ± 70 HU for the whole body, bone, and air in the patient, respectively. Random model errors of the proton range were small (<0.2 mm) for all spots and evenly distributed throughout the proton fields. Systematic errors of the proton range were -1.0(±2.2) mm and 0.4(±0.9)%, respectively, and were unevenly distributed within the proton fields. For 4.5% of the spots, large errors (>5 mm) were found, which may relate to MRI-CT mismatch due to, e.g., registration, MRI distortion anatomical changes, etc.

CONCLUSION

The sCT model was shown to be robust, i.e., had a low random model error. However, further investigation to reduce and even predict and manage systematic error is still needed for future MRI-only proton therapy.